{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-024269","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2026-06-05T20:09:22+00:00","discovered_at":"2026-06-05T20:10:00.270953+00:00","generated_at":"2026-06-05T20:20:56.042135+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Grace Therapeutics VP of Clinical Ops departing, will consult at $250/hr for NDA work","bullets":["Carrie D'Andrea, VP of Clinical Operations, to cease employment effective June 5, 2026.","She entered a 12-month consulting agreement at $250/hour for clinical development and NDA-related services.","Stock option awards will continue to vest during the consulting term and remain exercisable for 90 days after termination.","Severance benefits per November 2025 letter agreement, conditioned on release of claims and non-compete/non-solicitation covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-024269","json":"https://secwatch.observer/filing/0001140361-26-024269.json","markdown":"https://secwatch.observer/filing/0001140361-26-024269.md","text":"https://secwatch.observer/filing/0001140361-26-024269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/0001140361-26-024269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/ef20075612_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T20:20:56.042135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56608b07ac","claim":"Carrie D'Andrea departed as Vice President of Clinical Operations at Grace Therapeutics, Inc..","evidence_excerpt":"Carrie D’Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/0001140361-26-024269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving as Vice President of Clinical Operations"},{"label":"Role","value":"Vice President of Clinical Operations"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}